Filing Flows › Ultragenyx Pharmaceutical (RARE) › Guidance history
Ultragenyx Pharmaceutical (RARE) guidance history: what it guided and what it reported
Ultragenyx Pharmaceutical gave guidance in 3 earnings releases on file since May 5, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $730M–$760M (May 5, 2026) → reaffirmed $730M–$760M (Aug 4, 2026) → reaffirmed $730M–$760M (Nov 3, 2026) | — | to be reported | — |
The latest quarter
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
Questions
Does Ultragenyx Pharmaceutical beat its guidance?
Ultragenyx Pharmaceutical gave guidance in 3 earnings releases on file since May 5, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.